CURA Stock Overview
Operates a cannabis operator in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Curaleaf Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.07 |
| 52 Week High | CA$8.73 |
| 52 Week Low | CA$1.78 |
| Beta | 1.26 |
| 1 Month Change | -5.05% |
| 3 Month Change | -31.68% |
| 1 Year Change | -69.87% |
| 3 Year Change | -81.10% |
| 5 Year Change | -73.86% |
| Change since IPO | -75.85% |
Recent News & Updates
Here's Why Curaleaf Holdings (TSE:CURA) Has A Meaningful Debt Burden
Dec 15
Investors Give Curaleaf Holdings, Inc. (TSE:CURA) Shares A 27% Hiding
Nov 09Recent updates
Here's Why Curaleaf Holdings (TSE:CURA) Has A Meaningful Debt Burden
Dec 15Investors Give Curaleaf Holdings, Inc. (TSE:CURA) Shares A 27% Hiding
Nov 09Curaleaf Holdings, Inc. (TSE:CURA) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless
Aug 13These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively
Jul 19Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%
Jun 14Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%
Jan 19Does Curaleaf Holdings (CSE:CURA) Have A Healthy Balance Sheet?
Dec 11Is Curaleaf Holdings (CSE:CURA) Using Too Much Debt?
Sep 08Curaleaf Holdings (CSE:CURA) Has Debt But No Earnings; Should You Worry?
May 28We Think Curaleaf Holdings (CSE:CURA) Is Taking Some Risk With Its Debt
Sep 05Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden
May 20Is Curaleaf Holdings (CSE:CURA) A Risky Investment?
Oct 26Shareholder Returns
| CURA | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -9.6% | -3.8% | -0.1% |
| 1Y | -69.9% | -46.8% | 16.7% |
Return vs Industry: CURA underperformed the Canadian Pharmaceuticals industry which returned -47.4% over the past year.
Return vs Market: CURA underperformed the Canadian Market which returned 16.6% over the past year.
Price Volatility
| CURA volatility | |
|---|---|
| CURA Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 12.3% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: CURA has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: CURA's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 5,650 | Boris Jordan | www.curaleaf.com |
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Curaleaf Holdings, Inc. Fundamentals Summary
| CURA fundamental statistics | |
|---|---|
| Market cap | CA$1.56b |
| Earnings (TTM) | -CA$292.50m |
| Revenue (TTM) | CA$1.92b |
0.8x
P/S Ratio-5.3x
P/E RatioIs CURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURA income statement (TTM) | |
|---|---|
| Revenue | US$1.36b |
| Cost of Revenue | US$718.94m |
| Gross Profit | US$638.08m |
| Other Expenses | US$844.47m |
| Earnings | -US$206.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 03, 2025
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 47.02% |
| Net Profit Margin | -15.21% |
| Debt/Equity Ratio | 51.4% |
How did CURA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 10:09 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Curaleaf Holdings, Inc. is covered by 21 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Kenric Tyghe | ATB Capital Markets |
| Frederico Yokota Choucair Gomes | ATB Capital Markets |